Johnson & Johnson (J&J) has signed a collaboration deal with genomics diagnostics company Veracyte Inc. to advance the development of two nasal swab tests for early lung cancer detection.
Under the terms of the agreement, the Lung Cancer Initiative at J&J and Veracyte will combine clinical study cohorts with...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?